Keywords
COVID-19 Symptoms, Functional Status, Tertiary health care center, Bangladesh, Developing country
This article is included in the Emerging Diseases and Outbreaks gateway.
This article is included in the Health Services gateway.
The COVID-19 pandemic has affected people globally, causing widespread illness and functional limitations.
This cross-sectional study aimed to investigate the association between COVID-19 symptoms and the functional status of COVID-19 survivors at Bangabandhu Sheikh Mujib Medical University (BSMMU) in Bangladesh. A total of 244 COVID-19 survivors were enrolled in the study, and their symptoms and functional status were assessed using standardized questionnaires. The post-COVID-19 functional status scale (PCFS) was used to assess the entire range of functional outcomes.
Among the participants 57.4% were male and 42.6% were female. The mean (SD) age of the patients was 44.6 ±14.7 years where 37.7% were from the 20-35 years age group. The mean duration of suffering from COVID-19 was 15.9 ±6.1 days where 61.5 % of the patients had a duration of suffering of 11-20 days. Out of the 244 patients, 40 patients had no functional limitation (grade 0 functional status in the PCFS scale) while 100 had negligible functional limitation and 14 had severe functional limitation. We found patients who were suffering from multi-symptoms were statistically significant with PCFS scale grade 4, whereas grade 1 was found to be statistically significant with only respiratory distress. There was a significant association between the duration of COVID-19 symptoms and post-COVID-19 functional status for patients who experienced symptoms for 14 days or more (p<0.05).
Considering the negative impact of COVID-19 symptoms on functional status, comprehensive care and support are required for COVID-19 survivors.
COVID-19 Symptoms, Functional Status, Tertiary health care center, Bangladesh, Developing country
Reviewer comments were addressed. Some information was added in the procedure section. A new table was included.
See the authors' detailed response to the review by Parisa Rezaeifar
The COVID-19 pandemic has swept across the globe, affecting millions of people in 231 countries, areas, and territories and overwhelming healthcare systems. Bangladesh is one of the countries that has been severely affected by the pandemic, with 2.37 million cases and 29,445 deaths reported up to 26th March, 2023 (Worldometer). Coronaviruses are a family of enveloped viruses known as Coronaviridae. They are large, positive single-stranded RNA viruses that can be transmitted from human to human through respiratory secretions.1
COVID-19 is characterized by a range of clinical symptoms that appear 2-14 days after exposure to the virus, such as fever, cough, nasal congestion, fatigue, dyspnea, and severe chest symptoms consistent with pneumonia.2,3 The most common COVID-19 symptoms were fever (83%–98%), dry cough (57%–82%), and dyspnea (18%–55%), with a median duration of 5–8 days after the infection. Anosmia also presented in the early stages of the disease in the absence of other symptoms.3
It is expected that COVID-19 will have a noteworthy impact on physical, cognitive, mental, and social health, even among patients with mild illness.1 Previous studies on the long-term consequences of severe acute respiratory distress syndrome (ARDS) have shown negative effects on pulmonary function and overall health status that can persist for several years after the onset of the disease.4 A large proportion of patients experience fatigue, which reduces both physical and mental performance.5
According to the World Health Organization (WHO), quality of life (QOL) refers to an individual’s perception of their position in life within the context of the cultural and value systems they live in and their goals, expectations, standards, and concerns.6 Standard indicators of QOL include wealth, employment, physical and mental health, education, environment, leisure and recreational activities, social connections, religious beliefs, safety, security, and freedom. In patients who have recovered from COVID-19, their mental health may require a long-term recovery process, which can significantly impact their overall quality of life.1,7
A study found that general, respiratory, and gastrointestinal symptoms were associated with an increased risk of death due to COVID-19. Additionally, pre-existing conditions such as diabetes, cardiovascular diseases, and respiratory disease had a statistically significant association with the hospitalization of patients.3 Another study noted that many COVID-19 hospital survivors face adverse effects even six months after hospital discharge in terms of the level of physical activity and functional level decline in older adults.8
Functional capacity refers to an individual’s maximal ability to perform daily activities across various domains of life, such as physical, psychological, social, and spiritual. Meanwhile, functional performance refers to the actual activities that individuals carry out during their daily lives.1
Bangladesh is a developing country that has been severely affected by the pandemic, with thousands of cases and deaths reported.9 With the given number of COVID-19 survivors and their associated disabilities and financial constraints, their quality of life in terms of functional status in Bangladesh is negatively impacted.9,10 Like other low resource countries, in Bangladesh the healthcare system is underdeveloped where rehabilitation is not a health priority, and so COVID-19 survivors added an extra burden over healthcare delivery system.10
While many individuals have been able to recover from the disease, it is essential to understand the impact that COVID-19 can have on survivors’ functional status. This study aims to investigate the association between COVID-19 symptoms and functional status among COVID-19 survivors in a tertiary healthcare center in Bangladesh. By examining the functional status of survivors, this study seeks to shed light on the impact of COVID-19 on the physical, mental, and social wellbeing of those who have contracted the virus. These findings emphasize the importance of providing a comprehensive care and support to COVID-19 survivors beyond the acute phase of the illness to improve their functional outcomes and quality of life. Hence, an attempt was made to determine the association between COVID-19 symptoms and functional status among COVID-19 survivors in a tertiary health care center in a developing country.
The study received ethical clearance from the Institutional Review Board (IRB) of BSMMU (memo no: BSMMU/2020/9236, date of approval: 19-10-2020). Written informed consent was obtained from each participant prior to the commencement of the interview after assuring complete anonymity and no disclosure of their personal information. Participants with no education provided fingerprints on the consent form after receiving sufficient verbal explanation. This cross-sectional study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and no invasive procedure was involved.
The Post-COVID-19 functional status scale (PCFS) was used to cover the entire range of functional outcomes by focusing on limitations in usual duties/activities either at home/at work/study, as well as changes in lifestyle.11 The PCFS scale is a widely used tool to assess the functional limitations of COVID patients. It consists of five grades ranging from 0 (no functional limitation) to 4 (severe functional limitation). PCFS “0” denotes the complete absence of symptoms, and the individual is able to engage in all activities they could before to contracting COVID-19. PCFS “1” shows no symptoms when at rest, but there are restrictions on activities that call for strenuous physical effort or intense mental focus. PCFS “2” suggests symptoms while at rest, although the individual is capable of taking care of themselves. PCFS “3” denotes the requirement for some assistance with daily tasks like cooking, cleaning, or shopping. PCFS “4” denotes the requirement for assistance with daily living tasks like dressing or bathing.11 The PCFS scale is used to measure how COVID-19 will affect a person’s everyday functioning over the long run, and it can assist medical practitioners in determining whether the patient needs ongoing care and support. Researchers looking on the long-term impacts of COVID-19 on people and populations can also benefit from it.
This cross-sectional study was conducted from November 2020 to October 2021 in the Department of Physical Medicine & Rehabilitation at BSMMU. A total of 244 patients were selected according to the inclusion and exclusion criteria from the post-COVID-19 follow-up clinic under the Department of Medicine at BSMMU.
Sample size for this study was determined during protocol submission of IRB ethical clearance by using the formula n = z2pq/d2 = 382 (where n = sample size, z = 1.96 at 95% confidence level, p= prevalence of fatigue12 as post COVID-19 complication 53%, q = 1-p). Patients between the ages 18 and 90 years, irrespective of sex, who provided informed written consent and tested positive for COVID-19 through RT PCR test were included. Notably, those who had a history of major depressive illness, schizophrenia, mental retardation, or were on medication for psychiatric illness were excluded from the study due to their unique psychological profiles. All patients were recruited either two weeks after being discharged from the hospital or, for those who were not admitted to any hospital, two weeks after receiving a negative RT-PCR test result.
The interviews took place in the post-COVID-19 follow-up clinic where attendants were allowed to accompany participants during interview sessions. The hospital staff and medical personnel cooperated to ensure the success of the session. Wearing masks and maintaining a six-foot distance, both the participants and research assistants prioritized safety. The interview lasted for less than 30 minutes and the participants were assured of their right to withdraw themselves at any time without providing an explanation. They were informed that their participation was voluntary, and there were no incentives offered for their participation.
Data were collected by using a semi-structured questionnaire based on COVID-19 symptoms and complications through face-to-face interviews with trained research assistants. Participants were asked about sociodemographic variables and personal habits, alongside the duration of their COVID-19 attack, symptoms experienced during COVID-19 attack, co-morbidities, post COVID-19 complications and their quality of life, as evaluated by PCFS scale.
Data were analyzed using SPSS version 26. Continuous variables are provided with the appropriate mean and standard deviation. In categorical variables, frequency is shown. A Chi-square test was used to compare categorical variables amongst participants with varying degrees of functional impairment. A p value < 0.05 was regarded as statistically significant.
Within the specified time frame, a total of 280 participants agreed to participate in the study. However, 36 participants were subsequently excluded for various reasons. Specifically, 20 of them did not present their COVID-19 test result during the interview, 12 withdrew from the study due to time constraints or feeling unwell during the interview, and 4 were missing data. Among the 244 participants, 57.4 percent were male and 42.6 percent were female. The mean (SD) age of the patients was 44.6 (±14.7) years, where 37.7 percent were from 20-35 years age group. Again, the majority of the patients have above secondary level education (82), work as a service holder (56.6%) and came from nuclear family (67.2%). 63.9 percent of the patients had a monthly family income between 31000-60000 BDT. The mean duration of suffering, on the basis of how long patients had COVID-19 symptoms, was 15.9 (±6.1) days where 61.5 percent of the patients had a duration of 11-20 days (Table 1).
Out of the 244 patients, 40 (16.4%) patients had no functional limitation (grade 0 functional status in PCFS scale) while 100 (40.9%) had negligible functional limitation and 14 (5.7%) had severe functional limitation (Figure 1).
This study revealed that grade 0 was found to be statistically significant with fever, cough, respiratory distress, weakness or numbness of limbs, joint pain and skin rash or discoloration of fingers and toes. Grade 1 was found to be statistically significant (p < 0.001) with only respiratory distress and Grade 2 with weakness or numbness of limbs (p < 0.001). Grade 3 was found to be statistically significant (p < 0.001) with fever, cough, loss of taste, respiratory distress, and sore throat. Grade 3 was also found to be statistically significant (p < 0.05) with weakness or numbness of limbs and skin rash or discoloration of fingers and toes. Grade 4 was found to be statistically significant at p < 0.001 level with the symptoms of fever, fatigue, chest pain, and skin rash or discoloration of fingers and toes, whereas loss of taste, respiratory distress, sore throat, weakness or numbness of limbs were found statistically significant at p < 0.05 level (Table 2).
Symptoms | Functional status in PCFS scale frequency (%) (within column) | |||||
---|---|---|---|---|---|---|
Total (%) | Grade 0 (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) | |
Fever | ||||||
Yes | 218 (89.3) | 32 (80)* | 90 (90) | 38 (82.6) | 44 (100)** | 14 (100)** |
No | 26 (10.7) | 8 (20) | 10 (10) | 8 (17.4) | 0 (0) | 0 (0) |
Fatigue | ||||||
Yes | 164 (67.2) | 24 (60) | 62 (62) | 30 (65.2) | 34 (77.3) | 14 (100)** |
No | 80 (32.8) | 16 (40) | 38 (38) | 16 (34.8) | 10 (22.7) | 0 (0) |
Cough | ||||||
Yes | 160 (65.6) | 16 (40) | 62 (62) | 32 (69.6) | 38 (86.4)** | 12 (85.7) |
No | 84 (34.4) | 24 (60)** | 38 (38) | 14 (30.4) | 6 (13.6) | 2 (14.3) |
Loss of taste | ||||||
Yes | 136 (55.7) | 20 (50) | 50 (50) | 28 (60.9) | 34 (77.3)** | 4 (28.6) |
No | 108 (44.3) | 20 (50) | 50 (50) | 18 (39.1) | 10 (22.7) | 10 (71.4)* |
Loss of smell | ||||||
Yes | 126 (51.6) | 20 (50) | 52 (52) | 26 (56.5) | 24 (54.5) | 4 (28.6) |
No | 118 (48.4) | 20 (50) | 48 (48) | 20 (43.5) | 20 (45.5) | 10 (71.4) |
Respiratory distress | ||||||
Yes | 102 (41.8) | 8 (20) | 26 (26) | 20 (43.5) | 38 (86.4) | 10 (71.4)* |
No | 142 (58.2) | 32 (80)** | 74 (74)*** | 26 (56.5) | 6 (13.6)** | 4 (28.6) |
Sore throat | ||||||
Yes | 100 (41.0) | 14 (35) | 34 (34) | 20 (43.5) | 30 (68.2)** | 2 (14.3) |
No | 144 (59.0) | 26 (65) | 66 (66) | 26 (56.5) | 14 (31.8) | 12 (85.7)* |
Headache | ||||||
Yes | 80 (32.8) | 10 (25) | 30 (30) | 20 (43.5) | 16 (36.4) | 4 (28.6) |
No | 164 (67.2) | 30 (75) | 70 (70) | 26 (56.5) | 28 (63.6) | 10 (71.4) |
Body ache | ||||||
Yes | 76 (31.1) | 8 (20) | 34 (34) | 14 (30.4) | 14 (31.8) | 6 (42.9) |
No | 168 (68.9) | 32 (80) | 66 (66) | 32 (69.6) | 30 (68.2) | 8 (57.1) |
Sleep disturbance | ||||||
Yes | 70 (28.7) | 8 (20) | 24 (24) | 16 (34.8) | 18 (40.9) | 4 (28.6) |
No | 174 (71.3) | 32 (80) | 76 (76) | 30 (65.2) | 26 (59.1) | 10 (71.4) |
Weakness or numbness of limbs | ||||||
Yes | 64 (26.2) | 2 (5) | 24 (24) | 20 (43.5) | 18 (40.9) | 0 (0) |
No | 180 (73.8) | 38 (95)** | 76 (76) | 26 (56.5)** | 26 (59.1)* | 14 (100)* |
Loose motion | ||||||
Yes | 64 (26.2) | 8 (20) | 22 (22) | 14 (30.4) | 16 (36.4) | 4 (28.6) |
No | 180 (73.8) | 32 (80) | 78 (78) | 32 (69.6) | 28 (63.6) | 10 (71.4) |
Joint pain | ||||||
Yes | 64 (26.2) | 4 (10) | 28 (28) | 12 (26.1) | 16 (36.4) | 4 (28.6) |
No | 180 (73.8) | 36 (90)** | 72 (72) | 34 (73.9) | 28 (63.6) | 10 (71.4) |
Chest pain | ||||||
Yes | 36 (14.8) | 2 (5) | 10 (10) | 8 (17.4) | 8 (18.2) | 8 (57.1)** |
No | 208 (85.2) | 38 (95) | 90 (90) | 38 (82.6) | 36 (81.8) | 6 (42.9) |
Fear of death | ||||||
Yes | 28 (11.5) | 4 (10) | 10 (10) | 6 (13) | 6 (13.6) | 2 (14.3) |
No | 216 (88.5) | 36 (90) | 90 (90) | 40 (87) | 38 (86.4) | 12 (85.7) |
Skin rash or discoloration of finger toes | ||||||
Yes | 8 (3.3) | 0 (0) | 0 (0) | 0 (0) | 4 (9.1) | 4 (28.6) |
No | 236 (96.7) | 40 (100)* | 100 (100) | 46 (100) | 40 (90.9)* | 10 (71.4)** |
Patients with symptoms lasting 14 days or more had a higher percentage of functional limitations. The statistical analysis of the data revealed that there was a significant association between the duration of COVID-19 symptoms and post-COVID-19 functional status for patients who experienced symptoms for 14 days or more. Specifically, there was a statistically significant difference in the proportion of patients with grade 1, grade 3, and grade 4 functional status compared to those with symptoms lasting less than 14 days, with p-values of less than 0.05. However, for patients with symptoms lasting less than 14 days, there was no statistically significant association with post-COVID-19 functional status. Overall, these findings suggest that a longer duration of COVID-19 symptoms is associated with a higher risk of functional limitations in post-COVID-19 recovery (Table 3).
Duration of Symptoms | Total (%) | Functional status in PCFS scale frequency (%) (within column) | ||||
---|---|---|---|---|---|---|
Grade 0 (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) | ||
Below 14 days | 62 (25.4) | 10 (25) | 32 (32) | 14 (30.4) | 6 (13.6) | 0 (0) |
14 days and above | 182 (74.6) | 30 (75) | 68 (68)* | 32 (69.6) | 38 (86.4)* | 14 (100)** |
The majority of individuals aged 50 and below are in lower grades of PCFS (Grade 0 and 1), suggesting they have better functional status compared to those above age 50. Notably, 95% of those in Grade 0 and 72% in Grade 1 are under 50 years old. For the older group (Above 50), a significant percentage (85.7%) falls in Grade 4, indicating poorer functional status. The presence of significant p-values (p < 0.001 in Grade 4) highlights a statistically significant worse outcome in functional status among older individuals. A higher percentage of individuals in paid occupations tend to have better functional outcomes in the lower grades (Grade 0 and 1), with 70% in Grade 0 and 80% in Grade 1.
Conversely, individuals in unpaid occupations show higher frequencies in higher grades (Grade 3 and Grade 4), indicating poorer functional status. The difference in Grade 1 and Grade 3 is statistically significant with p < 0.05 and p < 0.001 respectively, suggesting that occupation type has a meaningful impact on functional status post-COVID-19. Non-smokers generally report better functional status, with 80% in Grade 0 and 90% in Grade 1. Smokers show a higher percentage in higher grades, such as Grade 3 (22.7%) and Grade 4 (28.6%). The difference in Grade 1 for non-smokers is statistically significant (*p < 0.05), indicating that smoking status may negatively impact post-COVID-19 recovery (Table 4).
Functional status in PCFS scale frequency (%) (within column) | |||||
---|---|---|---|---|---|
Grade 0 (%) | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) | |
Age group | |||||
50 and below | 38 (95) | 72 (72) | 28 (60.9) | 22 (50) | 2 (14.3) |
Above 50 | 2 (5)** | 28 (28) | 18 (39.1) | 22 (50)* | 12 (85.7)** |
Occupation | |||||
Unpaid | 12 (30) | 20 (20)** | 20 (43.5) | 24 (54.5)** | 6 (42.9) |
Paid | 28 (70) | 80 (80) | 26 (56.5) | 20 (45.5) | 8 (57.1) |
Smoking | |||||
Yes | 8 (20) | 10 (10)* | 6 (13) | 10 (22.7) | 4 (28.6) |
No | 32 (80) | 90 (90) | 40 (87) | 34 (77.3) | 10 (71.4) |
Our study investigated the association between COVID-19 symptoms and functional status among survivors in a tertiary health care center in Bangladesh, revealing insights into the post-recovery experiences of patients. The mean age of our cohort was 44.6 years, with a significant representation from the 20-35 age group, indicating a notable impact of COVID-19 across a younger demographic than typically emphasized in existing literature. This age group was considered to be relatively less vulnerable to COVID-19, and the high representation of this group might suggest a higher prevalence of the virus in the younger population of the studied area. The average age of the patients was found in earlier investigations to be 33.09 ± 12.09 years and 38.48 ± 16.20 years old respectively.9,13
There are differences in the clinical and demographic traits of COVID-19 individuals in a given population. Male patients make up 57.4% of the total population, with female patients making up the remaining 42.6%. These results were in line with some earlier research and global trends6,13–15 which represented both developed and developing nations. The study also sheds light on the diverse socio-economic backgrounds of COVID-19 survivors, revealing that a majority, or 56.6%, were employed individuals, and a substantial 82% had attained an education level beyond secondary school. This data suggests that COVID-19 affected a wide array of individuals, not limited by educational attainment or professional standing. Furthermore, the majority of participants, 67%, resided in nuclear families, in contrast to 37% who lived in extended (joint) family settings. On the economic front, a notable share of patients (63.9%) reported a monthly family income ranging from 31,000 to 60,000 Bangladeshi Taka. This group particularly experienced heightened financial strain during the pandemic due to considerable out-of-pocket healthcare expenses, which constituted roughly two-thirds of the total health expenditure in Bangladesh.16 Previous reports also showed that “vulnerable non-poor” families in Bangladesh have a monthly income between 35,000-70,000 BDT.
Our study’s findings reveal that older individuals, defined as those aged 50 and above, are disproportionately represented in the higher (more severe) grades of the PCFS which is consistent with an Egyptian study where age was found to be a significant risk factor for PCFS.17 This pattern suggests that older adults face a greater risk of poorer functional recovery, indicating a need for tailored medical and supportive interventions to improve their recovery prospects. Additionally, our analysis shows a clear disparity in functional outcomes based on occupational status. Individuals in unpaid occupations, which may include retirees, housewives, or the unemployed, tend to experience worse functional outcomes. In contrast, those in paid occupations, such as service holders and business owners, generally report better functional status. This distinction underscores the potential impact of economic activity and possibly socioeconomic status on recovery from COVID-19. Smoking status also appears to influence functional outcomes significantly. Smokers are less frequently found across all PCFS grades but are more concentrated in the severe impairment categories. Specifically, 28.6% of smokers are categorized under Grade 4, which represents a severe level of impairment. On the other hand, non-smokers are primarily found in the lower impairment grades, with 80% classified under Grade 0, indicating milder or no functional impairment. This distribution suggests that smoking may exacerbate the risk of severe post-COVID-19 functional impairments.
The average duration of COVID-19 symptoms among the participants indicated that the population experienced a form of the disease that was generally mild and consistent with standard infection periods. In contrast, Jradi et al.’s study reported a longer (35.31 ± 18.75) mean duration than the results of the current investigation.15 This long duration might be due to the impairment in physical activities, the long duration of confinement and the extreme doubt during the COVID-19 disease had generated remarkable mental and attitude disorders.18
In our study, a considerable number of the patients experienced varying degrees of functional limitation following COVID-19, with most facing mild to negligible impacts on their daily activities. However, a smaller subset encountered severe limitations, significantly hindering their daily functionality. The analysis did not cover the functional status of a portion of the participants. Similar results were mentioned by Machado et al.13 In similar study, Hussein et al., reported that most of participants (63.1%) had a trivial limitation in activities after recovery from COVID-19 (Grade 1), 14.1% had slight (Grade 2), 2.5% had moderate (Grade 3), and only 0.5% had severe functional limitation (Grade 4). However one fifth of the participants had no functional limitations (Grade 0).15 Another study conducted by Pant et al. showed negligible functional limitation (PCFS grade 1) among nearly one fourth (27.3%) of the patients, 13 (12.3%) patients had slight functional limitation (PCFS grade 2), and a negligible portion of the patients had moderate (PCFS grade 3) and severe functional limitations (PCFS grade 4).14
The present study describes the relationship between the functional status of patients and various symptoms they experienced. According to the statement, grade 0 functional status was statistically significant with fever, cough, respiratory distress, weakness or numbness of limbs, joint pain, and skin rash or discoloration of fingers and toes. This suggests that patients with grade 0 functional status were less likely to experience these symptoms compared to patients with higher functional status grades. Grade 1 functional status was found to be statistically significant with only respiratory distress, and grade 2 was found to be statistically significant with weakness or numbness of limbs. This indicates that patients with higher functional status grades were more likely to experience these symptoms compared to patients with lower functional status grades. Grade 3 functional status was statistically significant with fever, cough, loss of taste, respiratory distress, sore throat, weakness or numbness of limbs, and skin rash or discoloration of finger toes. Similarly, grade 4 functional status was statistically significant with fever, fatigue, loss of taste, respiratory distress, sore throat, weakness or numbness of limbs, chest pain, and skin rash or discoloration of fingers and toes. This suggests that patients with higher functional status grades were more likely to experience these symptoms compared to patients with lower functional status grades.
In a notable fraction of COVID-19 survivors, persistent symptoms have been linked to a progression toward low functional status.19 A higher percentage of people in a different study by Machado et al., who present a symptom-based COVID-19 diagnosis and have a lower functional level, such as living alone, have symptoms.14 Among individuals who had symptoms for at least 14 days, there was a significant correlation between the length of COVID-19 symptoms and post-COVID-19 functional status (p < 0.05). Longer symptom duration was linked to worse functional status in research by Huang et al., including decreased mobility and greater fatigue, discomfort, and depressive illness.20 The limitations of this study were firstly, the study used a convenience sampling technique, which may limit the generalizability of the findings. Secondly, the study relied on self-reported information, which may be subject to recall bias. Finally, the study was conducted in a single tertiary healthcare center, which may limit the generalizability of the findings to other settings.
This research will provide valuable insights into the association between COVID-19 symptoms and functional status of survivors in a developing country. The findings will be useful in developing effective rehabilitation programs for COVID-19 survivors and improving their quality of life.
Data cannot be made publicly available due to patient privacy concerns and the need to protect the confidentiality of research participants as specified on the consent form. The ethical committee has requested not to breach the confidentiality of the data and that the data should not be made publicly available.
To apply for access to the data, please contact the corresponding author (tariqulpmr@bsmmu.edu.bd). Applicants must maintain confidentiality, and there should be a reasonable cause to utilize these data only for research purposes. De-identified underlying data will be provided to approved applicants.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
No
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No
Are the conclusions drawn adequately supported by the results?
No
References
1. Buonacera A, Stancanelli B, Colaci M, Malatino L: Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. International Journal of Molecular Sciences. 2022; 23 (7). Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: COVID-19, iNFECTOUS DISEASES, BIOMARKERS OF INFLAMMATION, CADIOVASCULAR DISEASES
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
No
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: COVID-19 prognosis, Epidemiology
Is the work clearly and accurately presented and does it cite the current literature?
No
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: COVID-19, Post-COVID-19 Syndrome, Rehabilitation
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Pulmonary disease and intensive care medicine
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
No
If applicable, is the statistical analysis and its interpretation appropriate?
No
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Pulmonary disease and intensive care medicine
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Version 3 (revision) 23 Apr 24 |
read | read | read | |
Version 2 (revision) 23 Feb 24 |
read | |||
Version 1 25 May 23 |
read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)